论文部分内容阅读
目的 比对应用分支DNA-液相芯片技术和经典的OncotypeDx RT-PCR技术两种方法进行乳腺癌21基因检测结果的一致性,明确分支DNA-液相芯片技术可以作为临床常规检测的可行性方法,并结合乳腺癌的分子分型,预测患者的复发风险及化疗获益.方法 选取64例河南省肿瘤医院2010-2011年间的原发乳腺癌luminal型患者,应用分支DNA-液相芯片技术和经典的OncotypeDx RT-PCR比对检测21基因mRNA表达量,根据检测结果计算出RS值(复发风险评分),分值为0～100分.RS＜ 18分为低风险患者;18 ＜RS＜31为中风险患者;RS＞ 31为高风险患者.结果 64例标本中,应用分支DNA-液相芯片技术和经典的OncotypeDx RT-PCR比对检测21基因,二者结果一致性较高(93.8％);luminal A型病人,除1例外其余RS评分均小于18,全部为低复发风险,luminal B型病人,RS评分分布在6～56区间;luminal B型病人,内分泌治疗组的复发率为40％,内分泌加化疗组的复发率为6.7％.结论 应用B-DNA-液相芯片技术在LuminexX200平台检测乳腺癌21基因与经典OncotypeDx RT-PCR比对一致性高,此技术可以进行临床推广应用;基于免疫组化方法的乳腺癌分子分型,与乳腺癌21基因检测得出的RS风险评分相结合,预测患者复发风险及化疗获益准确度高.“,”Objective Aims to compare the consistency of OncotypeDx RT-PCR technology and DNA-liquid chip technology (branched,DNA,B-DNA) to show the DNA-liquid chip technology can be used as a feasible method for routine clinical detection,and combined with the molecular classification of breast cancer,it can predict the risk of recurrence and chemotherapy benefit in breast cancer patients.Methods Totally 64 primary breast cancer cases were selected from Henan Cancer Hospital during 2010-2011,then we calculated the RS value (recurrence risk score) within 0-100 score through mRNA expression of 21 gene detected by DNA-liquid chip technology and OncotypeDx RT-PCR,which means RS ＜ 18 low risk patients,18 ＜ RS ＜ 31 medium risk patients and 31 ＜ RS high risk patients.Results The compa ration results of DNA-liquid chip technology AND OncotypeDx RT-PCR to detect 21 genes showed the high consistency (93.8％) in 64 specimens,for type luminalA patients.There was only 1 cases (RS---20) the.RS scores were less than 18 in 39 cases enrolled,for luminalB group patients,the range of the RS score distribution was 6-56,he recurrence rate was 40％ and the recurrence rate of the ndocrine plus chemotherapy group was 6.7％ in luminalB groups patients.Conclusion The application of B-DNA-liquid chip technology on Luminex X200 platform had high consistency comparing the classic RT-PCR OncotypeDx in the detection of breast cancer 21 gene,and this technology can be used for clinical application.The combination of molecular classification based on immunohistochemical method and RS score obtained by 21 breast cancer detection had the high accuracy which could predict the recurrence risk and chemotherapy benefit in breast cancer.